Company Filing History:
Years Active: 1999
Title: David Austen Perry: Innovator in Antiparasitic Agents
Introduction
David Austen Perry, an accomplished inventor based in Groton, Connecticut, has made significant strides in the field of medicine through his innovative research on antiparasitic agents. His work focuses on providing advancements in treatments for parasitic infections in both animals and humans.
Latest Patents
David is credited with one patent, which addresses the development of 5-oximino-25-substituted avermectin B1 or B2 monosaccharides. This invention falls under the category of antiparasitic agents related to milbemycins and avermectins, offering new opportunities for treating various parasitic infections. The compounds he has developed may be synthesized from corresponding 5-keto substituted derivatives, showcasing his contribution to both veterinary and human medical applications.
Career Highlights
Throughout his career, David has worked with Pfizer Corporation, a leading company in pharmaceutical innovation. His tenure at Pfizer has allowed him to explore and develop cutting-edge solutions in the field of parasitology, solidifying his reputation as a forward-thinking inventor.
Collaborations
David has collaborated with notable coworkers, including Bernard Frank Bishop and Michael Stephen Pacey. Their combined expertise and dedication to research have enriched the projects they've undertaken together, resulting in impactful advancements in medical treatments.
Conclusion
In summary, David Austen Perry represents a significant figure in the realm of medical innovations with his pioneering work on antiparasitic agents. His contributions not only enhance our understanding of parasitic infections but also pave the way for more effective treatment options. As he continues to work alongside esteemed colleagues at Pfizer, the future of his innovative endeavors promises to yield even more groundbreaking discoveries.